Recipharm
Abstract: A Swedish biotechnology company called Betagenon was ready to take its new drug candidate O304 to clinical trials. The molecule is an AMP-activated protein kinase (AMPK) activator for the treatment of chronic energy balance disorders in metabolically challenged elderly and/or obese individuals. Clinical Trial Consultants (CTC) and Recipharm were selected to perform the work needed to reach the customer's important phase I milestone.
Description:
Category: Drug Product
Type: Small Molecules
Contact: Evelina Videll ([email protected])